News

Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining

The new facility expands the company’s capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based in California

RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport. The therapy is encapsulated within lipid nanoparticles and directly administered to

The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority. It is due to open

The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement and trademark

The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It supports low-to-high

This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1) mutation is

The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and

The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada’s network and rare disease